 |
 |
PRESS RELEASE: Costly Polytherapy and an Aging Population will Fuel Steady Expansion of the Parkinson's Disease Market Monday February 23, 8:06 am ET Novartis/Orion's Comtan Franchise Set To Grow Fivefold Over the Next Ten Years According to a New Study from Decision Resources WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the Parkinson's disease (PD) market will grow steadily in the next ten years as populations age and polytherapy becomes the norm in both the early and more advanced stages of the disease. A new study entitled Parkinson's Disease finds that the newer, more expensive therapies such as dopamine agonists will boost the number of PD patients taking polytherapy, thus increasing the overall drug market's value. "Novel therapies designed to improve patients' responses to levodopa will greatly expand the PD market over the next decade," said Tricia Nagle, analyst at Decision Resources. "Also fueling this sector will be continued growth by current market leaders, including Novartis/Orion's Comtan, GlaxoSmithKline's Requip, and Pfizer/Boehringer Ingelheim's Mirapex/Sifrol. Overall drug sales for PD in the major markets in 2012 will more than double 2002 sales." About Parkinson's Disease The chronic, progressive nature of PD and the fact that no currently available treatments slow or stop the disease's progression make it an attractive target for drug development. Moreover, an ever-growing elderly population that will lead to a steadily increasing number of PD sufferers over the next decade renders the PD market a highly lucrative area of opportunity. About Pharmacor from Decision Resources Pharmacor is a unique family of studies that assess a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development. About Decision Resources Decision Resources, Inc., http://www.decisionresources.com is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [log in to unmask] Source: Decision Resources, Inc. SOURCE: Yahoo News (press release) http://biz.yahoo.com/prnews/040223/nem001_1.html * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn